Research outputs
Selected research outputs
- Short term managment of agitation associated with psychotic or bipolar disorders: a systematic review (Conference Paper - 2013)
- A systematic review of prevention and intervention strategies for populations at high risk of engaging in violent behaviour: update 2002-8 (Journal article - 2012)
- Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses (Journal article - 2011)
- Biofeedback for hypertension: a systematic review (Journal article - 2010)
- The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation (Journal article - 2010)
- Case study of the comparison of data from conference abstracts and full-text articles in health technology assessment of rapidly evolving technologies: Does it make a difference? (Journal article - 2006)
- Searching for and use of conference abstracts in health technology assessments: Policy and practice (Journal article - 2006)
- Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies (Journal article - 2006)
- Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis (Journal article - 2004)
- Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation (Journal article - 2004)
2026
Avelumab in combination with axitinib for advanced renal cell carcinoma [ID1547]: A Single Technology Appraisal
Fleeman, N., Lambe, T., Nevitt, S., Mahon, J., Beale, S., Boland, A., . . . Waddell, T. (2026). Avelumab in combination with axitinib for advanced renal cell carcinoma [ID1547]: A Single Technology Appraisal. Retrieved from https://njl-admin.nihr.ac.uk/document/download/2033490
2025
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]: A Single Technology Appraisal
Bresnahan, R., Harvey, R., Stainthorpe, A., Bryning, S., Beale, S., Boland, A., . . . Malik, Z. (2025). Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]: A Single Technology Appraisal. Retrieved from https://www.nice.org.uk/guidance/ta1086/documents/committee-papers-2
Guselkumab for treating moderately to severely active ulcerative colitis [ID6237]: A Cost comparison Technology Appraisal
Fleeman, N., Stainthorpe, A., Chaplin, M., Huang, V., Dundar, Y., McEntee, J., & Bodger, K. (2025). Guselkumab for treating moderately to severely active ulcerative colitis [ID6237]: A Cost comparison Technology Appraisal. Retrieved from https://www.nice.org.uk/guidance/ta1094/history
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]: A Single Technology Appraisal
Fleeman, N., Stainthorpe, A., Beale, S., Boland, A., Chaplin, M., Greenhalgh, J., . . . Lord, R. (2025). Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]: A Single Technology Appraisal. Retrieved from https://www.nice.org.uk/guidance/ta1055/documents/committee-papers
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]: A Single Technology Appraisal
Fleeman, N., Stainthorpe, A., Beale, S., Boland, A., Chaplin, M., Bresnahan, R., . . . Campbell, L. (2025). Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]: A Single Technology Appraisal. Retrieved from https://www.nice.org.uk/guidance/ta1042/documents/committee-papers
2024
Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small cell lung cancer (Review of TA662) [ID6404]
Fleeman, N., Bryning, S., Beale, S., Boland, A., Dundar, Y., Marsden, A., & Green, J. (2024). Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small cell lung cancer (Review of TA662) [ID6404]. Retrieved from https://www.nice.org.uk/guidance/TA1041
Talazoparib for HER2-negative locally advanced or metastatic breast cancer with germline BRCA1/2-mutations [ID1342]: A Single Technology Appraisal
Fleeman, N., Bresnahan, R., Mahon, J., Chaplin, M., Beale, S., Boland, A., . . . Palmieri, C. (2024). Talazoparib for HER2-negative locally advanced or metastatic breast cancer with germline BRCA1/2-mutations [ID1342]: A Single Technology Appraisal. Retrieved from https://www.nice.org.uk/
Olaparib for maintenance treatment of BRCA-mutated ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (Review of TA598) [ID6191]: A Single Technology Appraisal.
Greenhalgh, J., Stainthorpe, A., Chaplin, M., Beale, S., Boland, A., Dundar, Y., . . . Green, J. (2024). Olaparib for maintenance treatment of BRCA-mutated ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (Review of TA598) [ID6191]: A Single Technology Appraisal.. Retrieved from https://www.nice.org.uk/guidance/ta962/documents/committee-papers
Nivolumab-relatlimab for untreated unresectable or metastatic melanoma [ID1688]: A Single Technology Appraisal.
Bresnahan, R., Fleeman, N., Stainthorpe, A., Bryning, S., Nevitt, S., Mahon, J., . . . Danson, S. (2024). Nivolumab-relatlimab for untreated unresectable or metastatic melanoma [ID1688]: A Single Technology Appraisal.. Retrieved from https://www.nice.org.uk/guidance/ta950/documents/committee-papers
2023
Upadacitinib for treating moderately to severely active ulcerative colitis [ID3953]
Greenhalgh, J., Mahon, J., Houten, R., Edwards, K., Donegan, S., Boland, A., . . . Mcentee, J. (2023). Upadacitinib for treating moderately to severely active ulcerative colitis [ID3953]: Upadacitinib for treating moderately to severely active ulcerative colitis[ID3953]. Retrieved from https://www.fundingawards.nihr.ac.uk/award/NIHR135585
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15 (vol 7, pg 863, 2023)
Chaplin, M., Bresnahan, R., Fleeman, N., Mahon, J., Houten, R., Beale, S., . . . Munot, P. (2023). Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15 (vol 7, pg 863, 2023). PHARMACOECONOMICS-OPEN, 7(6), 1015. doi:10.1007/s41669-023-00462-7
Momelotinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis [ID6141]: A Single Technology Appraisal
Fleeman, N., Bresnahan, R., Mahon, J., Bryning, S., Beale, S., Boland, A., . . . Butt, N. (2023). Momelotinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis [ID6141]: A Single Technology Appraisal. Retrieved from https://www.nice.org.uk/guidance/ta957/evidence/committee-papers-pdf-13363268509
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
Chaplin, M., Bresnahan, R., Fleeman, N., Mahon, J., Houten, R., Beale, S., . . . Munot, P. (2023). Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - Open. doi:10.1007/s41669-023-00439-6
Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bresnahan, R., Houten, R., Greenhalgh, J., Nevitt, S., Mahon, J., Beale, S., . . . Chaplin, M. (2023). Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.. PharmacoEconomics - open. doi:10.1007/s41669-023-00408-z
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Houten, R., Fleeman, N., Mahon, J., Chaplin, M., Edwards, K., Beale, S., . . . Palmieri, C. (2023). Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN. doi:10.1007/s41669-023-00405-2
Headache Diagnosis: When is a Migraine not a Middle Class Tension Headache?
Gabbay, M., & Dundar, Y. (2023). Headache Diagnosis: When is a Migraine not a Middle Class Tension Headache?. In The Evidence-Based Primary Care Handbook (pp. 231-234). CRC Press. doi:10.1201/9781003420293-25
Helicobacter Pylori
Gabbay, M., & Dundar, Y. (2023). Helicobacter Pylori. In The Evidence-Based Primary Care Handbook (pp. 252-259). CRC Press. doi:10.1201/9781003420293-29
Urinary Tract Infections: Test or Treat and How to Treat?
Dundar, Y., & Mair, F. (2023). Urinary Tract Infections: Test or Treat and How to Treat?. In The Evidence-Based Primary Care Handbook (pp. 245-251). CRC Press. doi:10.1201/9781003420293-28
2022
Onasemnogene abeparvovec for treating pre-symptomatic spinal muscular atrophy (MAA partial review of HST 15) [ID4051]: A Highly Specialised Technology appraisal
Bresnahan, R., Fleeman, N., Mahon, J., Houten, R., Chaplin, M., Beale, S., . . . Munot, P. (2022). Onasemnogene abeparvovec for treating pre-symptomatic spinal muscular atrophy (MAA partial review of HST 15) [ID4051]: A Highly Specialised Technology appraisal. Retrieved from https://www.nice.org.uk/guidance/hst24/history
2021
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]
Bresnahan, R., Houten, R., Mahon, J., Beale, S., Nevitt, S., Greenhalgh, J., . . . Gandhi, S. (2021). Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]: Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/rebecca-bresnahan/
Nivolumab in combination with chemotherapy for untreated advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma [ID1465]
Greenhalgh, J., Mahon, J., Nevitt, S., Bresnahan, R., Boland, A., Beale, S., . . . Boon, C. (2021). Nivolumab in combination with chemotherapy for untreated advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma [ID1465]: Nivolumab in combination with chemotherapy for untreated advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma [ID1465]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
Greenhalgh, J., Boland, A., Bates, V., Vecchio, F., Dundar, Y., Chaplin, M., & Green, J. A. (2021). First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (3). doi:10.1002/14651858.CD010383.pub3
Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Houten, R., Greenhalgh, J., Mahon, J., Nevitt, S., Beale, S., Boland, A., . . . McEntee, J. (2021). Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 5(1), 13-22. doi:10.1007/s41669-020-00206-x
2020
Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]
Bresnahan, R., Mahon, J., Nevitt, S., Beale, S., Boland, A., Greenhalgh, J., . . . Campbell, L. (2020). Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]: Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/rebecca-bresnahan/
Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Stainthorpe, A., Fleeman, N., Houten, R., Chaplin, M., Boland, A., Beale, S., . . . Syndikus, I. (2020). Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 4(4), 563-574. doi:10.1007/s41669-020-00203-0
Sapropterin dihydrochloride for treating phenylketonuria [ID1475]
Greenhalgh, J., James, M., Nevitt, S., Bresnahan, R., Beale, S., Boland, A., . . . Schwan, B. (2020). Sapropterin dihydrochloride for treating phenylketonuria [ID1475]: Sapropterin dihydrochloride for treating phenylketonuria [ID1475]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
Brigatinib for ALK-positive advanced non-small cell lung cancer that has not been previously treated with an ALK inhibitor [ID1468]
Greenhalgh, J., Lambe, T., Mahon, J., Nevitt, S., Edwards, K., Bresnahan, R., . . . Green, J. (2020). Brigatinib for ALK-positive advanced non-small cell lung cancer that has not been previously treated with an ALK inhibitor [ID1468]: Brigatinib for ALK-positive advanced non-small cell lung cancer that has not been previously treated with an ALK inhibitor [ID1468]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
Midostaurin for treating advanced systemic mastocytosis [ID1573]
Greenhalgh, J., Lambe, T., Nevitt, S., Mahon, J., Boland, A., Beale, S., . . . Moonim, M. (2020). Midostaurin for treating advanced systemic mastocytosis [ID1573]: Midostaurin for treating advanced systemic mastocytosis [ID1573]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
Antiepileptic drugs as prophylaxis for postcraniotomy seizures
Greenhalgh, J., Weston, J., Dundar, Y., Nevitt, S. J., & Marson, A. G. (2020). Antiepileptic drugs as prophylaxis for postcraniotomy seizures. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (4). doi:10.1002/14651858.CD007286.pub5
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]
Greenhalgh, J., Fleeman, N., Houten, R., Chaplin, M., Beale, S., Boland, A., . . . Goodson, N. (2020). Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]: Ixekizumab for treating axial spondyloarthritis after NSAIDs[ID1532]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
Fleeman, N., Houten, R., Bagust, A., Richardson, M., Beale, S., Boland, A., . . . Shenoy, A. (2020). Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 24(2), 1-+. doi:10.3310/hta24020
2019
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
Fleeman, N., Houten, R., Chaplin, M., Beale, S., Boland, A., Dundar, Y., . . . Shenoy, A. (2019). A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC CANCER, 19(1). doi:10.1186/s12885-019-6369-7
Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Fleeman, N., Mahon, J., Nevitt, S., Duarte, R., Boland, A., Kotas, E., . . . Ahmad, S. (2019). Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 3(4), 453-461. doi:10.1007/s41669-019-0138-z
Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck
Greenhalgh, J., Mahon, J., Chaplin, M., Nevitt, S., Boland, A., Beale, S., . . . Shaw, R. (2019). Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck: Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck (17/56/06). NICE website. Retrieved from https://www.nice.org.uk/guidance/gid-ta10181/documents/committee-papers
Atezolizumab for untreated, locally advanced or metastatic, triple negative breast cancer
Greenhalgh, J., Mahon, J., Chaplin, M., Beale, S., Boland, A., Lambe, T., . . . Palmieri, C. (2019). Atezolizumab for untreated, locally advanced or metastatic, triple negative breast cancer: Atezolizumab for untreated, locally advanced or metastatic, triple negative breast cancer (128748). NICE website. Retrieved from https://www.nice.org.uk/guidance/gid-ta10433/documents/committee-papers
Heated Humidified High-Flow Nasal Cannula for Preterm Infants: An Updated Systematic Review and Meta-analysis
Fleeman, N., Dundar, Y., Shah, P. S., & Shaw, B. N. J. (2019). Heated Humidified High-Flow Nasal Cannula for Preterm Infants: An Updated Systematic Review and Meta-analysis. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 35(4), 298-306. doi:10.1017/S0266462319000424
2018
Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer
Fleeman, N., Mahon, J., Chaplin, M., Boland, A., Beale, S., De Sousa Rego Vieira Duarte, R., . . . Green, J. (2018). Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer: Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non- small-cell lung cancer (17/141/08). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta621/documents/committee-papers
Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma (17/56/12)
Fleeman, N., Stainthorpe, A., Houten, R., Chaplin, M., Boland, A., Beale, S., . . . Isabel, S. (2018). Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma (17/56/12): Brentuximab vedotin for treating relapsed or refractory CD30- positive cutaneous T-cell lymphoma (17/56/12). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta577/documents/committee-papers
Encorafenib in combination with binimetinib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma
Greenhalgh, J., Mahon, J., Nevitt, S., Beale, S., Boland, A., Lambe, T., . . . Danson, S. (2018). Encorafenib in combination with binimetinib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma: Encorafenib in combination with binimetinib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma (17/109/14). NICE website. Retrieved from https://www.nice.org.uk/guidance/ta562/documents/committee-papers
Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Greenhalgh, J., Mahon, J., Nevitt, S., Beale, S., Boland, A., Lambe, T., . . . Marshall, E. (2018). Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (17/109/17). NICE website. Retrieved from https://www.nice.org.uk/guidance/ta553/documents/committee-papers
Antiepileptic drugs as prophylaxis for postcraniotomy seizures (Review)
Greenhalgh, J., Weston, J., Dundar, Y., Nevitt, S. J., & Marson, A. G. (2018). Antiepileptic drugs as prophylaxis for postcraniotomy seizures (Review). COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (5). doi:10.1002/14651858.CD007286.pub4
A systematic review of the diagnostic accuracy of automated tests for cognitive impairment
Aslam, R. W., Bates, V., Dundar, Y., Hounsome, J., Richardson, M., Krishan, A., . . . Sikdar, S. (2018). A systematic review of the diagnostic accuracy of automated tests for cognitive impairment. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 33(4), 561-575. doi:10.1002/gps.4852
2017
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059]
Fleeman, N., Houten, R., Bagust, A., Chaplin, M., Beale, S., Boland, A., . . . Shenoy, A. (2017). Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059] (ID1059). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta535/documents/assessment-report
2016
Automated tests for diagnosing and monitoring cognitive impairment: a diagnostic accuracy review
Aslam, R. W., Bates, V., Dundar, Y., Hounsome, J., Richardson, M., Krishan, A., . . . Robinson, L. (2016). Automated tests for diagnosing and monitoring cognitive impairment: a diagnostic accuracy review. Health Technology Assessment, 20(77). doi:10.3310/hta20770
Pharmacological treatment of acute agitation associated with psychotic and bipolar disorder: a systematic review and meta-analysis
Dundar, Y., Greenhalgh, J., Richardson, M., & Dwan, K. (2016). Pharmacological treatment of acute agitation associated with psychotic and bipolar disorder: a systematic review and meta-analysis. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 31(4), 268-285. doi:10.1002/hup.2535
First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
Greenhalgh, J., Dwan, K., Boland, A., Bates, V., Vecchio, F., Dundar, Y., . . . Green, J. A. (2016). First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD010383.pub2
A web resource for mining HLA associations with adverse drug reactions: HLA-ADR.
Ghattaoraya, G. S., Dundar, Y., González-Galarza, F. F., Maia, M. H. T., Santos, E. J. M., da Silva, A. L. S., . . . Jones, A. R. (2016). A web resource for mining HLA associations with adverse drug reactions: HLA-ADR.. Database : the journal of biological databases and curation, 2016, baw069. doi:10.1093/database/baw069
The clinical effectiveness and cost-effectiveness of heated humidified high-flow nasal cannula compared with usual care for preterm infants: systematic review and economic evaluation
Fleeman, N., Mahon, J., Bates, V., Dickson, R., Dundar, Y., Dwan, K., . . . Shaw, B. N. J. (2016). The clinical effectiveness and cost-effectiveness of heated humidified high-flow nasal cannula compared with usual care for preterm infants: systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 20(30), 1-67. doi:10.3310/hta20300
2015
The clinical effectiveness and cost-effectiveness of the PROGENSA (R) prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation
Nicholson, A., Mahon, J., Boland, A., Beale, S., Dwan, K., Fleeman, N., . . . Dundar, Y. (2015). The clinical effectiveness and cost-effectiveness of the PROGENSA (R) prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation. Health Technology Assessment, 19(87), 1-+. doi:10.3310/hta19870
Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective
Fleeman, N., Bagust, A., Beale, S., Boland, A., Dickson, R., Dwan, K., . . . Banks, L. (2015). Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective. PHARMACOECONOMICS, 33(9), 893-904. doi:10.1007/s40273-015-0276-9
Corrigendum: Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown, T., Pilkington, G., Bagust, A., Boland, A., Oyee, J., Tudur Smith, C., . . . Dickson, R. (2015). Corrigendum: Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 17(31), 281-282. doi:10.3310/hta17310-c201505
Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal
Greenhalgh, J., Bagust, A., Boland, A., Oyee, J., Trevor, N., Beale, S., . . . O'Reilly, S. (2015). Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal. PharmacoEconomics, 33(2), 137-148. doi:10.1007/s40273-014-0214-2
A scoping study to explore the cost-effectiveness of next-generation sequencing compared with traditional genetic testing for the diagnosis of learning disabilities in children
Beale, S., Sanderson, D., Sanniti, A., Dundar, Y., & Boland, A. (2015). A scoping study to explore the cost-effectiveness of next-generation sequencing compared with traditional genetic testing for the diagnosis of learning disabilities in children. HEALTH TECHNOLOGY ASSESSMENT, 19(46), I-90. doi:10.3310/hta19460
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation
Greenhalgh, J., Bagust, A., Boland, A., Dwan, K., Beale, S., Hockenhull, J., . . . Marshall, E. (2015). Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 19(47), I-133. doi:10.3310/hta19470
Moderators of the effect of psychological interventions on depression and anxiety in cardiac surgery patients: A systematic review and meta-analysis
Protogerou, C., Fleernan, N., Dwan, K., Richardson, M., Dundar, Y., & Hagger, M. S. (2015). Moderators of the effect of psychological interventions on depression and anxiety in cardiac surgery patients: A systematic review and meta-analysis. BEHAVIOUR RESEARCH AND THERAPY, 73, 151-164. doi:10.1016/j.brat.2015.08.004
Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
Fleeman, N., Bagust, A., Beale, S., Dwan, K., Dickson, R., Proudlove, C., & Dundar, Y. (2015). Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer. PHARMACOECONOMICS, 33(1), 13-23. doi:10.1007/s40273-014-0206-2
Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis
Greenhalgh, J., Bagust, A., Boland, A., Dwan, K., Beale, S., Fleeman, N., . . . Fisher, M. (2015). Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. HEALTH TECHNOLOGY ASSESSMENT, 19(29), 1-+. doi:10.3310/hta19290
Systematic review to examine the clinical effectiveness and tolerability of chemotherapy for older people with non - Hodgkin’s lymphoma
Pilkington, G., Greenhalgh, J., Aslam, R. W., Boland, A., Joanne, F., Dickson, R. C., . . . Bates, V. (2015). Systematic review to examine the clinical effectiveness and tolerability of chemotherapy for older people with non - Hodgkin’s lymphoma: Systematic review to examine the clinical effectiveness and tolerability of chemotherapy for older people with non-Hodgkin’s lymphoma.
Systematic review to examine the clinical effectiveness and tolerability of systemic anti-cancer therapy for older people with chronic myeloid leukaemia
Bates, V., Pilkington, G. M., Dickson, R. C., Boland, A., Dundar, Y., & Clark, R. (2015). Systematic review to examine the clinical effectiveness and tolerability of systemic anti-cancer therapy for older people with chronic myeloid leukaemia.
Systematic review to examine the clinical effectiveness and tolerability of chemotherapy treatment for older people with colorectal cancer
Pilkington, G. M., Boland, A., Dickson, R. C., Bates, V., Dundar, Y., & Saunders, M. (2015). Systematic review to examine the clinical effectiveness and tolerability of chemotherapy treatment for older people with colorectal cancer.
2014
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Greenhalgh, J., Bagust, A., Beale, S., Boland, A., Chaplin, M., Dwan, K., . . . Hall, M. (2014). Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (14/15/01). NICE website. Retrieved from https://www.nice.org.uk/
Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma
Fleeman, N., Bagust, A., Beale, S., Boland, A., Dickson, R., Dwan, K., . . . Banks, L. (2014). Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma: Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma (12/54). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta321/history
Allopurinol for the treatment of chronic kidney disease: a systematic review
Fleeman, N., Pilkington, G., Dundar, Y., Dwan, K., Boland, A., Dickson, R., . . . Pyatt, J. (2014). Allopurinol for the treatment of chronic kidney disease: a systematic review. HEALTH TECHNOLOGY ASSESSMENT, 18(40), 1-+. doi:10.3310/hta18400
EFFICACY OF PSYCHOLOGICAL INTERVENTIONS TO REDUCE DISTRESS IN PATIENTS UNDERGOING INVASIVE CARDIAC PROCEDURES: A META-ANALYSIS
Protogerou, C., Fleeman, N. F., Dwain, K. D., Richardson, M. R., Dundar, Y. D., & Dickson, R. D. (2014). EFFICACY OF PSYCHOLOGICAL INTERVENTIONS TO REDUCE DISTRESS IN PATIENTS UNDERGOING INVASIVE CARDIAC PROCEDURES: A META-ANALYSIS. In INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE Vol. 21 (pp. S63). Retrieved from https://www.webofscience.com/
2013
Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal
Beale, S., Dickson, R., Bagust, A., Blundell, M., Dundar, Y., Boland, A., . . . Proudlove, C. (2013). Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal. PHARMACOECONOMICS, 31(12), 1121-1129. doi:10.1007/s40273-013-0094-x
A systematic review of risk assessment strategies for populations at high risk of engaging in violent behaviour: update 2002-8.
Whittington, R., Hockenhull, J. C., McGuire, J., Leitner, M., Barr, W., Cherry, M. G., . . . Dickson, R. (2013). A systematic review of risk assessment strategies for populations at high risk of engaging in violent behaviour: update 2002-8.. Health technology assessment (Winchester, England), 17(50), i-128. doi:10.3310/hta17500
Description of health problem
Brown, T., Pilkington, G., Bagust, A., Boland, A., Oyee, J., Smith, C. T., . . . Dickson, R. (2013). Description of health problem. HEALTH TECHNOLOGY ASSESSMENT, 17(31), 1-+. doi:10.3310/hta17310
1181 – Short-term Management Of Agitation Associated With Psychotic Or Bipolar Disorders: a Systematic Review
Dundar, Y., & Greenhalgh, J. (2013). 1181 – Short-term Management Of Agitation Associated With Psychotic Or Bipolar Disorders: a Systematic Review. European Psychiatry, 28(S1). doi:10.1016/s0924-9338(13)76266-7
A systematic review of risk assessment strategies for populations at high risk of engaging in violent behaviour: update 2002-8
Whittington, R., Hockenhull, J. C., McGuire, J., Leitner, M., Barr, W., Cherry, M. G., . . . Dickson, R. (2013). A systematic review of risk assessment strategies for populations at high risk of engaging in violent behaviour: update 2002-8. HEALTH TECHNOLOGY ASSESSMENT, 17(50), 1-+. Retrieved from https://www.webofscience.com/
Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review
Brown, T., Pilkington, G., Boland, A., Oyee, J., Smith, C. T., Dundar, Y., . . . Dickson, R. (2013). Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review. HEALTH TECHNOLOGY ASSESSMENT, 17(6), 1-+. doi:10.3310/hta17060
Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review
Brown, T., Pilkington, G., Boland, A., Oyee, J., Tudur Smith, C., Dundar, Y., . . . Dickson, R. (2013). Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review. Health Technology Assessment, 17(6), 1-99. doi:10.3310/hta17060
Erlotinib in monoterapia nel trattamento di mantenimento del carcinoma polmonare non a piccole cellule dopo chemioterapia a base di platino
Dickson, R., Bagust, A., Boland, A., Blundell, M., Davis, H., Dundar, Y., . . . Ramani, V. S. (2013). Erlotinib in monoterapia nel trattamento di mantenimento del carcinoma polmonare non a piccole cellule dopo chemioterapia a base di platino. PharmacoEconomics Italian Research Articles, 15(1), 35-44. doi:10.1007/s40276-013-0004-4
Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin's Lymphoma A NICE Single Technology Appraisal
Greenhalgh, J., Bagust, A., Boland, A., Blundell, M., Oyee, J., Beale, S., . . . Chu, P. (2013). Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin's Lymphoma A NICE Single Technology Appraisal. PHARMACOECONOMICS, 31(5), 403-413. doi:10.1007/s40273-013-0043-8
SHORT-TERM MANAGEMENT OF AGITATION ASSOCIATED WITH PSYCHOTIC OR BIPOLAR DISORDERS: A SYSTEMATIC REVIEW
Dundar, Y., & Greenhalgh, J. (2013). SHORT-TERM MANAGEMENT OF AGITATION ASSOCIATED WITH PSYCHOTIC OR BIPOLAR DISORDERS: A SYSTEMATIC REVIEW. In EUROPEAN PSYCHIATRY Vol. 28. Retrieved from https://www.webofscience.com/
Short term managment of agitation associated with psychotic or bipolar disorders: a systematic review
Dundar, Y., Dwan, K., & Greenhalgh, J. (2013). Short term managment of agitation associated with psychotic or bipolar disorders: a systematic review. In European Congress of Psychiatry (pp. 1). Nice: EPA.
2012
A systematic review of prevention and intervention strategies for populations at high risk of engaging in violent behaviour: update 2002-8.
Hockenhull, J. C., Whittington, R., Leitner, M., Barr, W., McGuire, J., Cherry, M. G., . . . Dickson, R. (2012). A systematic review of prevention and intervention strategies for populations at high risk of engaging in violent behaviour: update 2002-8.. Health technology assessment (Winchester, England), 16(3), 1-152.
A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy.
Hockenhull, J., Elremeli, M., Cherry, M. G., Mahon, J., Lai, M., Darroch, J., . . . Boyle, R. (2012). A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy.. Health technology assessment (Winchester, England), 16(12).
The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation
Cherry, M. G., Greenhalgh, J., Osipenko, L., Venkatachalam, M., Boland, A., Dundar, Y., . . . Rees, D. C. (2012). The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 16(43), 1-+. Retrieved from https://www.webofscience.com/
A systematic review of prevention and intervention strategies for populations at high risk of engaging in violent behaviour: Update 2002-8
Hockenhull, J. C., Whittington, R., Leitner, M., Barr, W., McGuire, J., Cherry, M. G., . . . Dickson, R. (2012). A systematic review of prevention and intervention strategies for populations at high risk of engaging in violent behaviour: Update 2002-8. doi:10.3310/hta16030
A systematic review of prevention and intervention strategies for populations at high risk of engaging in violent behaviour: update 2002-8
Hockenhull, J. C., Whittington, R., Leitner, M., Barr, W., McGuire, J., Cherry, M. G., . . . Dickson, R. (2012). A systematic review of prevention and intervention strategies for populations at high risk of engaging in violent behaviour: update 2002-8. HEALTH TECHNOLOGY ASSESSMENT, 16(3), 1-+. doi:10.3310/hta16030
A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy
Hockenhull, J., Elremeli, M., Cherry, M. G., Mahon, J., Lai, M., Darroch, J., . . . Boyle, R. (2012). A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy. HEALTH TECHNOLOGY ASSESSMENT, 16(12), 1-+. doi:10.3310/hta16120
2011
Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy A NICE Single Technology Appraisal
Dickson, R., Bagust, A., Boland, A., Blundell, M., Davis, H., Dundar, Y., . . . Ramani, V. S. (2011). Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy A NICE Single Technology Appraisal. PHARMACOECONOMICS, 29(12), 1051-1062. doi:10.2165/11591600-000000000-00000
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis
Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Oyee, J., Blundell, M., . . . Fisher, M. (2011). Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. HEALTH TECHNOLOGY ASSESSMENT, 15(31), 1-+. doi:10.3310/hta15310
The clinical effectiveness and cost-effectiveness of genotyping for <i>CYP2D6</i> for the management of women with breast cancer treated with tamoxifen: a systematic review
Fleeman, N., Martin Saborido, C., Payne, K., Boland, A., Dickson, R., Dundar, Y., . . . Walley, T. (2011). The clinical effectiveness and cost-effectiveness of genotyping for <i>CYP2D6</i> for the management of women with breast cancer treated with tamoxifen: a systematic review. HEALTH TECHNOLOGY ASSESSMENT, 15(33), XIII-+. doi:10.3310/hta15330
Cetuximab nel carcinoma ricorrente e/o metastatico a cellule squamose della testa e del collo. Una valutazione di tecnologia singola del NICE
Bagust, A., Greenhalgh, J., Boland, A., Fleeman, N., McLeod, C., Dickson, R., . . . Shaw, R. (2011). Cetuximab nel carcinoma ricorrente e/o metastatico a cellule squamose della testa e del collo. Una valutazione di tecnologia singola del NICE. PharmacoEconomics Italian Research Articles, 13(2), 101-110. doi:10.1007/bf03320687
Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses
Fleeman, N., Dundar, Y., Dickson, R., Jorgensen, A., Pushpakom, S., McLeod, C., . . . Walley, T. (2011). Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. PHARMACOGENOMICS JOURNAL, 11(1), 1-14. doi:10.1038/tpj.2010.73
Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer (NSCLC)
Dickson, R., Bagust, A., Boland, A., Blundell, M., Brown, T., Davis, H., . . . Ramani, V. (2011). Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer (NSCLC). Health Technology Assessment, in pre.
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis
Fleeman, N., Bagust, A., Boland, A., Dickson, R., Dundar, Y., Moonan, M., . . . Thorp, N. (2011). Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. HEALTH TECHNOLOGY ASSESSMENT, 15(42), 1-+. doi:10.3310/hta15420
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma: A Single Technology Appraisal
Greenhalgh, J., Bagust, A., Boland, A., Blundell, M., Oyee, J., Dundar, Y., . . . Chu, P. (2011). Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma: A Single Technology Appraisal.
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma: A Single Technology Appraisal
Greenhalgh, J., Bagust, A., Boland, A., Blundell, M., Oyee, J., Dundar, Y., . . . Chu, P. (2011). Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma: A Single Technology Appraisal.
Ticagrelor for the treatment of acute coronary syndromes: A Single Technology Appraisal
Greenhalgh, J., Bagust, A., Boland, A., Blundell, M., Lai, M., Dundar, Y., . . . Fisher, M. (2011). Ticagrelor for the treatment of acute coronary syndromes: A Single Technology Appraisal.
2010
Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
Brown, T., Boland, A., Bagust, A., Oyee, J., Hockenhull, J., Dundar, Y., . . . Proudlove, C. (2010). Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 14, 71-79. doi:10.3310/hta14suppl2/10
Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
Brown, T., Boland, A., Bagust, A., Oyee, J., Hockenhull, J., Dundar, Y., . . . Proudlove, C. (2010). Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technology Assessment, 14(Suppl 2), 71-79. doi:10.3310/hta14suppl2-10
Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer
Greenhalgh, J., McLeod, C., Bagust, A., Boland, A., Fleeman, N., Dundar, Y., . . . Pearson, M. (2010). Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. Health Technology Assessment, 14(Suppl 2), 33-39. doi:10.3310/hta14suppl2-05
Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck A NICE Single Technology Appraisal
Bagust, A., Greenhalgh, J., Boland, A., Fleeman, N., McLeod, C., Dickson, R., . . . Shaw, R. (2010). Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck A NICE Single Technology Appraisal. PHARMACOECONOMICS, 28(6), 439-448. doi:10.2165/11532220-000000000-00000
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
Fleeman, N., Bagust, A., McLeod, C., Greenhalgh, J., Boland, A., Dundar, Y., . . . Pearson, M. (2010). Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technology Assessment, 14(Suppl 1), 47-53. doi:10.3310/hta14suppl1-07
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention
Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Fleeman, N., McLeod, C., . . . Fisher, M. (2010). Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. Health Technology Assessment, 14(Suppl 1), 31-38. doi:10.3310/hta14suppl1-05
Abatacept for the treatment of rheumatoid arthritis
Hockenhull, J., Boland, A., Bagust, A., Dundar, Y., Fleeman, N., Kennedy, T., . . . Dickson, R. (2010). Abatacept for the treatment of rheumatoid arthritis. Health Technology Assessment. Retrieved from http://www.hta.ac.uk/project/1648.asp
Biofeedback for hypertension: a systematic review
Greenhalgh, J., Dickson, R., & Dundar, Y. (2010). Biofeedback for hypertension: a systematic review. JOURNAL OF HYPERTENSION, 28(4), 644-652. doi:10.1097/HJH.0b013e3283370e20
Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes (Retracted Article)
Greenhalgh, J., Hockenhull, J., Rao, N., Dundar, Y., Dickson, R. C., & Bagust, A. (2010). Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes (Retracted Article). COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (5). doi:10.1002/14651858.CD004587.pub2
Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Brown, T., Boland, A., Bagust, A., Oyee, J., Hockenhull, J., Dundar, Y., . . . Proudlove, C. (2010). Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.. Health technology assessment (Winchester, England), 14(Suppl. 2), 71-79. doi:10.3310/hta14suppl2/10
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
Fleeman, N., Bagust, A., McLeod, C., Greenhalgh, J., Boland, A., Dundar, Y., . . . Pearson, M. (2010). Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 14, 47-53. doi:10.3310/hta14suppl1/07
Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer
Greenhalgh, J., McLeod, C., Bagust, A., Boland, A., Fleeman, N., Dundar, Y., . . . Pearson, M. (2010). Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 14, 33-39. doi:10.3310/hta14suppl2/05
Pemetrexed for the treatment of relapsed non-small cell lung cancer
Hockenhull, J., Boland, A., Bagust, A., Dundar, Y., Davis, H., Dickson, R., . . . Proudlove, N. (2010). Pemetrexed for the treatment of relapsed non-small cell lung cancer. Health Technology Assessment. Retrieved from http://www.hta.ac.uk/erg/reports/1641.pdf
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention
Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Fleeman, N., McLeod, C., . . . Fisher, M. (2010). Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. HEALTH TECHNOLOGY ASSESSMENT, 14, 31-38. doi:10.3310/hta14suppl1/05
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention
Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Fleeman, N., McLeod, C., . . . Fisher, M. (2010). Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. Health Technology Assessment, 14(Suppl 1). doi:10.3310/hta14suppl1/05
The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation
Fleeman, N., McLeod, C., Bagust, A., Beale, S., Boland, A., Dundar, Y., . . . Dickson, R. (2010). The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 14(3), 1-+. doi:10.3310/hta14030
2009
Erlotinib for the treatment of relapsed non-small cell lung cancer
McLeod, C., Bagust, A., Boland, A., Hockenhull, J., Dundar, Y., Proudlove, C., . . . Dickson, R. (2009). Erlotinib for the treatment of relapsed non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 13, 41-47. doi:10.3310/hta13suppl1/07
Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma
Dundar, Y., Bagust, A., Hounsome, J., McLeod, C., Boland, A., Davis, H., . . . Dickson, R. (2009). Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma. HEALTH TECHNOLOGY ASSESSMENT, 13, 23-28. doi:10.3310/hta13suppl1/04
Monozygotic twinning, cerebral palsy and congenital anomalies
Pharoah, P. O. D., & Dundar, Y. (2009). Monozygotic twinning, cerebral palsy and congenital anomalies. HUMAN REPRODUCTION UPDATE, 15(6), 639-648. doi:10.1093/humupd/dmp019
Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
Greenhalgh, J., Bagust, A., Boland, A., Fleeman, N., McLeod, C., Dundar, Y., . . . Shaw, R. (2009). Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Health Technology Assessment, 13(Suppl 3), 49-54. doi:10.3310/hta13suppl3-08
The effects of biofeedback for the treatment of essential hypertension: a systematic review
Greenhalgh, J., Dickson, R., & Dundar, Y. (2009). The effects of biofeedback for the treatment of essential hypertension: a systematic review. HEALTH TECHNOLOGY ASSESSMENT, 13(46), 1-+. doi:10.3310/hta13460
The effects of biofeedback for the treatment of essential hypertension: a systematic review.
Greenhalgh, J., Dickson, R., & Dundar, Y. (2009). The effects of biofeedback for the treatment of essential hypertension: a systematic review.. Health technology assessment (Winchester, England), 13(46), 1-104. doi:10.3310/hta13460
Rituximab for the treatment of rheumatoid arthritis
Bagust, A., Boland, A., Hockenhull, J., Fleeman, N., Greenhalgh, J., Dundar, Y., . . . Dickson, R. (2009). Rituximab for the treatment of rheumatoid arthritis. Health Technology Assessment, 13(Suppl 2), 23-29. doi:10.3310/hta13suppl2-04
Erlotinib for the treatment of relapsed non-small cell lung cancer
McLeod, C., Bagust, A., Boland, A., Hockenhull, J., Dundar, Y., Proudlove, C., . . . Dickson, R. (2009). Erlotinib for the treatment of relapsed non-small cell lung cancer. Health Technology Assessment, 13(Suppl 1), 41-47. doi:10.3310/hta13suppl1-07
Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin’s lymphoma
Dundar, Y., Bagust, A., Hounsome, J., McLeod, C., Boland, A., Davis, H., . . . Dickson, R. (2009). Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin’s lymphoma. Health Technology Assessment, 13(Suppl 1), 23-28. doi:10.3310/hta13suppl1/04
Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin’s lymphoma
Dundar, Y., Bagust, A., Hounsome, J., McLeod, C., Boland, A., Davis, H., . . . Dickson, R. (2009). Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin’s lymphoma. Health Technology Assessment, 13(Suppl 1), 23-28. doi:10.3310/hta13suppl1-04
Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
Greenhalgh, J., Bagust, A., Boland, A., Fleeman, N., McLeod, C., Dundar, Y., . . . Shaw, R. (2009). Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. HEALTH TECHNOLOGY ASSESSMENT, 13, 49-54. doi:10.3310/hta13suppl3/08
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation
McLeod, C., Fleeman, N., Kirkham, J., Bagust, A., Boland, A., Chu, P., . . . Walley, T. (2009). Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 13(1), 1-+. doi:10.3310/hta13010
Rituximab for the treatment of rheumatoid arthritis
Bagust, A., Boland, A., Hockenhull, J., Fleeman, N., Greenhalgh, J., Dundar, Y., . . . Dickson, R. (2009). Rituximab for the treatment of rheumatoid arthritis. HEALTH TECHNOLOGY ASSESSMENT, 13, 23-29. doi:10.3310/hta13suppl2/04
2008
The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation.
Hockenhull, J. C., Dwan, K., Boland, A., Smith, G., Bagust, A., Dündar, Y., . . . Dickson, R. (2008). The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 12(12), iii-154. doi:10.3310/hta12120
The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation: Abstract
Hockenhull, J. C., Dwan, K., Boland, A., Smith, G., Bagust, A., Duendar, Y., . . . Dickson, R. (2008). The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation: Abstract. HEALTH TECHNOLOGY ASSESSMENT, 12(12), 1-+. Retrieved from https://www.webofscience.com/
So many filters, so little time: the development of a search filter appraisal checklist
Glanville, J., Bayliss, S., Booth, A., Dundar, Y., Fernandes, H., Fleeman, N. D., . . . Welch, K. (2008). So many filters, so little time: the development of a search filter appraisal checklist. JOURNAL OF THE MEDICAL LIBRARY ASSOCIATION, 96(4), 356-361. doi:10.3163/1536-5050.96.4.011
The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: A systematic review and economic evaluation
Hockenhull, J. C., Dwan, K., Boland, A., Smith, G., Bagust, A., Dündar, Y., . . . Dickson, R. (2008). The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: A systematic review and economic evaluation. Health Technology Assessment, 12(12). doi:10.3310/hta12120
2007
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma
Green, J., Dundar, Y., Dodd, S., Dickson, R., & Walley, T. (2007). Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (1). doi:10.1002/14651858.CD005574.pub2
Adverse events associated with intravenous iron infusion (low‐molecular‐weight iron dextran and iron sucrose): a systematic review
CRITCHLEY, J., & DUNDAR, Y. (2007). Adverse events associated with intravenous iron infusion (low‐molecular‐weight iron dextran and iron sucrose): a systematic review. Transfusion Alternatives in Transfusion Medicine, 9(1), 8-36. doi:10.1111/j.1778-428x.2007.00042.x
Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod, C., Bagust, A., Boland, A., Dagenais, P., Dickson, R., Dundar, Y., . . . Walley, T. (2007). Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 11(28), 1-iv. doi:10.3310/hta11280
Drug-eluting stents: a systematic review and economic evaluation.
Hill, R. A., Boland, A., Dickson, R., Dündar, Y., Haycox, A., McLeod, C., . . . Bagust, A. (2007). Drug-eluting stents: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 11(46), iii-221. doi:10.3310/hta11460
Pemetrexed disodium for the treatment of malignant pleural mesothelioma: A systematic review and economic evaluation
Dundar, Y., Bagust, A., Dickson, R., Dodd, S., Green, J., Haycox, A., . . . Walley, T. (2007). Pemetrexed disodium for the treatment of malignant pleural mesothelioma: A systematic review and economic evaluation. Health Technology Assessment, 11(1). doi:10.3310/hta11010
Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation
Dundar, Y., Bagust, A., Dickson, R., Dodd, S., Green, J., Haycox, A., . . . Walley, T. (2007). Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 11(1), 1-+. Retrieved from https://www.webofscience.com/
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma
Green, J., Dundar, Y., Dodd, S., Dickson, R., & Walley, T. (2007). Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma. Cochrane Database of Systematic Reviews, (1). doi:10.1002/14651858.CD005574.pub2
2006
Case study of the comparison of data from conference abstracts and full-text articles in health technology assessment of rapidly evolving technologies: Does it make a difference?
Dundar, Y., Dodd, S., Williamson, P., Dickson, R., & Walley, T. (2006). Case study of the comparison of data from conference abstracts and full-text articles in health technology assessment of rapidly evolving technologies: Does it make a difference?. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 22(3), 288-294. doi:10.1017/S0266462306051166
Searching for and use of conference abstracts in health technology assessments: Policy and practice
Dundar, Y., Dodd, S., Williamson, P., Walley, T., & Dickson, R. (2006). Searching for and use of conference abstracts in health technology assessments: Policy and practice. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 22(3), 283-287. doi:10.1017/S0266462306051154
Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies
Dundar, Y., Dodd, S., Dickson, R., Walley, T., Haycox, A., & Williamson, P. R. (2006). Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies. Health Technology Assessment, 10(5).
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma
Green, J., Dundar, Y., Dodd, S., Dickson, R., & Walley, T. (2006). Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma. In J. Green (Ed.). John Wiley & Sons, Ltd. doi:10.1002/14651858.cd005574
Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies
Dundar, Y., Dodd, S., Dickson, R., Walley, T., Haycox, A., & Williamson, P. R. (2006). Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies. Health Technology Assessment, 10(5), 1-162. Retrieved from http://www.hta.ac.uk/project.asp?PjtId=1433
Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies
Dundar, Y., Dodd, S., Dickson, R., Walley, T., Haycox, A., & Williamson, P. R. (2006). Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies. HEALTH TECHNOLOGY ASSESSMENT, 10(5), III-+. Retrieved from https://www.webofscience.com/
2005
Percutaneous transluminal coronary angioplasty with stents versus coronary artery bypass grafting for people with stable angina or acute coronary syndromes
Bakhai, A., Hill, R. A., Dundar, Y., Dickson, R., & Walley, T. (2005). Percutaneous transluminal coronary angioplasty with stents versus coronary artery bypass grafting for people with stable angina or acute coronary syndromes. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (1). doi:10.1002/14651858.CD004588.pub3
Drug-eluting stents versus non-drug eluting stents in people with stable angina or acute coronary syndrome
Bakhai, A., Hill, R. A., Dundar, Y., Dickson, R. C., & Walley, T. (2004). Drug-eluting stents versus non-drug eluting stents in people with stable angina or acute coronary syndrome. doi:10.1002/14651858.cd004587
Pemetrexed disodium for the treatment of malignant mesothelioma:systematic review
Dundar, Y., Haycox, A., & Green, J. A. (2005). Pemetrexed disodium for the treatment of malignant mesothelioma:systematic review. health Technology Assessment, 04/17, 95.
Stents versus coronary artery bypass graft in people with stable angina or acute coronary syndrome
Bakhai, A., Hill, R. A., Dundar, Y., Dickson, R., & Walley, T. (2004). Stents versus coronary artery bypass graft in people with stable angina or acute coronary syndrome. doi:10.1002/14651858.cd004588.pub2
Stents versus coronary artery bypass graft in people with stable angina or acute coronary syndrome
Bakhai, A., Hill, R. A., Dundar, Y., Dickson, R., & Walley, T. (2002). Stents versus coronary artery bypass graft in people with stable angina or acute coronary syndrome. doi:10.1002/14651858.cd004588
2004
Exploring groups at high risk of restenosis
Bagust, A., Bakhai, A., Dickson, R., Dundar, Y., Hill, R. A., & Walley, T. (2004). Exploring groups at high risk of restenosis. EUROPEAN HEART JOURNAL, 25(23), 2168-2169. doi:10.1016/j.ehj.2004.09.028
Angioplasty and stents in coronary artery disease: a systematic review and meta-analysis
Dündar, Y., Hill, R. A., Bakhai, A., Dickson, R., & Walley, T. (2004). Angioplasty and stents in coronary artery disease: a systematic review and meta-analysis. SCANDINAVIAN CARDIOVASCULAR JOURNAL, 38(4), 200-210. doi:10.1080/14017430410032325
A systematic review of the research on communication between patients and heatth care professionats about medicines: the consequences for concordance
Stevenson, F. A., Cox, K., Britten, N., & Dundar, Y. (2004). A systematic review of the research on communication between patients and heatth care professionats about medicines: the consequences for concordance. HEALTH EXPECTATIONS, 7(3), 235-245. doi:10.1111/j.1369-7625.2004.00281.x
Drug-eluting stents: An early systematic review to inform policy
Hill, R. A., Dündar, Y., Bakhai, A., Dickson, R., & Walley, T. (2004). Drug-eluting stents: An early systematic review to inform policy. ACC Current Journal Review, 13(8), 41. doi:10.1016/j.accreview.2004.07.099
Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis
Dündar, Y., Dodd, S., Strobl, J., Boland, A., Dickson, R., & Walley, T. (2004). Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 19(5), 305-322. doi:10.1002/hup.594
Drug-eluting stents: an early systematic review to inform policy
Hill, R. A., Dündar, Y., Bakhai, A., Dickson, R., & Walley, T. (2004). Drug-eluting stents: an early systematic review to inform policy. EUROPEAN HEART JOURNAL, 25(11), 902-919. doi:10.1016/j.ehj.2004.03.023
Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.
Dündar, Y., Boland, A., Strobl, J., Dodd, S., Haycox, A., Bagust, A., . . . Walley, T. (2004). Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 8(24), iii-125. doi:10.3310/hta8240
Coronary artery stents: a rapid systematic review and economic evaluation
Hill, R., Bagust, A., Bakhai, A., Dickson, R., Dündar, Y., Haycox, A., . . . Walley, T. (2004). Coronary artery stents: a rapid systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 8(35), 1-+. Retrieved from https://www.webofscience.com/
Coronary artery stents: a rapid systematic review and economic evaluation.
Hill, R., Bagust, A., Bakhai, A., Dickson, R., Dündar, Y., Haycox, A., . . . Walley, T. (2004). Coronary artery stents: a rapid systematic review and economic evaluation.. Health technology assessment (Winchester, England), 8(35), iii-242. doi:10.3310/hta8350
Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation
Dundar, Y., Boland, A., Strobl, J., Dodd, S., Haycox, A., Bagust, A., . . . Walley, T. (2004). Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technology Assessment, 8(24), 1-140.
Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation
Dündar, Y., Boland, A., Strobl, J., Dodd, S., Haycox, A., Bagust, A., . . . Walley, T. (2004). Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 8(24), 1-+. Retrieved from https://www.webofscience.com/
2003
PCV36 COST-EFFECTIVENESS OF EARLY THROMBOLYSIS FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION: A SYSTEMATIC REVIEW OF THE LITERATURE
Boland, A., Haycox, A. R., Mujita-Mota, R., Dundar, Y., Bagust, A., Dickson, R., & Walley, T. (2003). PCV36 COST-EFFECTIVENESS OF EARLY THROMBOLYSIS FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION: A SYSTEMATIC REVIEW OF THE LITERATURE. Value in Health, 6(6), 656. doi:10.1016/s1098-3015(10)61680-4
PNM18 COST-EFFECTIVENESS OF Z DRUGS (ZOLPIDEM, ZOPICLONE AND ZALEPLON) VERSUS BENZODIAZEPINES FOR THE SHORT—TERM MANAGEMENT OF INSOMNIA: A SYSTEMATIC LITERATURE REVIEW
Boland, A., Haycox, A. R., Dundar, Y., Dickson, R., & Walley, T. (2003). PNM18 COST-EFFECTIVENESS OF Z DRUGS (ZOLPIDEM, ZOPICLONE AND ZALEPLON) VERSUS BENZODIAZEPINES FOR THE SHORT—TERM MANAGEMENT OF INSOMNIA: A SYSTEMATIC LITERATURE REVIEW. Value in Health, 6(6), 768. doi:10.1016/s1098-3015(10)61957-2
Early thrombosis for the treatment of acute myocardial infarction: A systematic review and economic evaluation
Boland, A., Dundar, Y., Bagust, A., Haycox, A., Hill, R., Mujica Mota, R., . . . Dickson, R. (2003). Early thrombosis for the treatment of acute myocardial infarction: A systematic review and economic evaluation. Health Technology Assessment, 7(15).
Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review
Dundar, Y., Hill, R., Dickson, R., & Walley, T. (2003). Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 96(2), 103-113. doi:10.1093/qjmed/hcg016
Superiority and equivalence in thrombolytic drugs: an interpretation
Walley, T., Dundar, Y., Hill, R., & Dickson, R. (2003). Superiority and equivalence in thrombolytic drugs: an interpretation. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 96(2), 155-160. doi:10.1093/qjmed/hcg020
Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.
Boland, A., Dundar, Y., Bagust, A., Haycox, A., Hill, R., Mujica Mota, R., . . . Dickson, R. (2003). Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 7(15), 1-136. doi:10.3310/hta7150